Insight

Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24

Photo of Gilberto Lopes taken from med.miami.edu

May 27, 2024, 13:04

Gilberto Lopes: Few of the positive trials we have data for in lung cancer from ASCO24

Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X: .

“Alright!

ASCO abstracts are out. Most plenary and oral are LBAs so not out yet. Let’s check a few of the positive trials we have data for in lung cancer.

HARMONi-A – ivonescimab, an anti-PD-1/VEGF bispecific antibody, added to chemo vs chemo alone after EGFR TKI shows clinically relevant improvement in PFS!

322 patients randomized. 85%+ has 3rd gen – HR 0.46 [0.34, 0.62], P < 0.0001. Clearly positive.

New options for treatment are welcome. No OS data yet. Trial from China. Shouldn’t matter. But that has created challenges for approval in the US recently.”

Gilberto Lopes

Source: Gilberto Lopes/X

anti-PD-1/VEGF ASCO ASCO24 cancer Gilberto Lopes HARMONi-A ivonescimab Lung cancer OncoDaily Oncology positive trials Sylvester Comprehensive Cancer Center

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage